Selected research
Industry Research
IBS Treatment Industry Research Report 2026
Market perspective
The global IBS Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the IBS Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the IBS Treatment market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the IBS Treatment market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of IBS Treatment include Takeda Pharmaceutical Company (Japan), Nestle (Switzerland), Novartis (Switzerland), Pfizer (U.S.), Synthetic Biologics (U.S.), Synergy Pharmaceuticals (U.S.), Sucampo Pharmaceuticals (U.S.), Sebela Pharmaceuticals (Ireland) and RedHill Biopharma (Israel), among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global IBS Treatment market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to IBS Treatment.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
IBS Treatment Market by Company
Takeda Pharmaceutical Company (Japan)
Nestle (Switzerland)
Novartis (Switzerland)
Pfizer (U.S.)
Synthetic Biologics (U.S.)
Synergy Pharmaceuticals (U.S.)
Sucampo Pharmaceuticals (U.S.)
Sebela Pharmaceuticals (Ireland)
RedHill Biopharma (Israel)
Protagonist Therapeutics (U.S.)
Probi (Sweden)
Lexicon Pharmaceuticals (U.S.)
Ironwood Pharmaceuticals (U.S.)
Ipsen (France)
Innovate Biopharmaceuticals (U.S.)
Bausch Health
AstraZeneca (U.K)
Astellas Pharma (Japan)
Ardelyx (U.S.)
Allergan (Ireland)
Alfasigma USA (Italy)
Abbott Laboratories (U.S.)
IBS Treatment Segment by Type
IBS-D
IBS-C
IBS-M
IBS Treatment Segment by Application
Hospitals
Clinics
Research Laboratories
IBS Treatment Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IBS Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of IBS Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IBS Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of IBS Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- IBS-D
- IBS-C
- IBS-M
Applications
- Hospitals
- Clinics
- Research Laboratories
Companies covered
- Takeda Pharmaceutical Company (Japan)
- Nestle (Switzerland)
- Novartis (Switzerland)
- Pfizer (U.S.)
- Synthetic Biologics (U.S.)
- Synergy Pharmaceuticals (U.S.)
- Sucampo Pharmaceuticals (U.S.)
- Sebela Pharmaceuticals (Ireland)
- RedHill Biopharma (Israel)
- Protagonist Therapeutics (U.S.)
- Probi (Sweden)
- Lexicon Pharmaceuticals (U.S.)
- Ironwood Pharmaceuticals (U.S.)
- Ipsen (France)
- Innovate Biopharmaceuticals (U.S.)
- Bausch Health
- AstraZeneca (U.K)
- Astellas Pharma (Japan)
- Ardelyx (U.S.)
- Allergan (Ireland)
- Alfasigma USA (Italy)
- Abbott Laboratories (U.S.)
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 IBS Treatment by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 IBS-D
- 2.2.3 IBS-C
- 2.2.4 IBS-M
- 2.3 IBS Treatment by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospitals
- 2.3.3 Clinics
- 2.3.4 Research Laboratories
- 2.4 Assumptions and Limitations
3 IBS Treatment Breakdown Data by Type
- 3.1 Global IBS Treatment Historic Market Size by Type (2021-2026)
- 3.2 Global IBS Treatment Forecasted Market Size by Type (2027-2032)
4 IBS Treatment Breakdown Data by Application
- 4.1 Global IBS Treatment Historic Market Size by Application (2021-2026)
- 4.2 Global IBS Treatment Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global IBS Treatment Market Perspective (2021-2032)
- 5.2 Global IBS Treatment Growth Trends by Region
- 5.2.1 Global IBS Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 IBS Treatment Historic Market Size by Region (2021-2026)
- 5.2.3 IBS Treatment Forecasted Market Size by Region (2027-2032)
- 5.3 IBS Treatment Market Dynamics
- 5.3.1 IBS Treatment Industry Trends
- 5.3.2 IBS Treatment Market Drivers
- 5.3.3 IBS Treatment Market Challenges
- 5.3.4 IBS Treatment Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top IBS Treatment Players by Revenue
- 6.1.1 Global Top IBS Treatment Players by Revenue (2021-2026)
- 6.1.2 Global IBS Treatment Revenue Market Share by Players (2021-2026)
- 6.2 Global IBS Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of IBS Treatment Head Office and Area Served
- 6.4 Global IBS Treatment Players, Product Type & Application
- 6.5 Global IBS Treatment Manufacturers Established Date
- 6.6 Global IBS Treatment Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America IBS Treatment Market Size (2021-2032)
- 7.2 North America IBS Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America IBS Treatment Market Size by Country (2021-2026)
- 7.4 North America IBS Treatment Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe IBS Treatment Market Size (2021-2032)
- 8.2 Europe IBS Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe IBS Treatment Market Size by Country (2021-2026)
- 8.4 Europe IBS Treatment Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific IBS Treatment Market Size (2021-2032)
- 9.2 Asia-Pacific IBS Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific IBS Treatment Market Size by Country (2021-2026)
- 9.4 Asia-Pacific IBS Treatment Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America IBS Treatment Market Size (2021-2032)
- 10.2 South America IBS Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America IBS Treatment Market Size by Country (2021-2026)
- 10.4 South America IBS Treatment Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa IBS Treatment Market Size (2021-2032)
- 11.2 Middle East & Africa IBS Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa IBS Treatment Market Size by Country (2021-2026)
- 11.4 Middle East & Africa IBS Treatment Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Takeda Pharmaceutical Company (Japan)
- 12.1.1 Takeda Pharmaceutical Company (Japan) Company Information
- 12.1.2 Takeda Pharmaceutical Company (Japan) Business Overview
- 12.1.3 Takeda Pharmaceutical Company (Japan) Revenue in IBS Treatment Business (2021-2026)
- 12.1.4 Takeda Pharmaceutical Company (Japan) IBS Treatment Product Portfolio
- 12.1.5 Takeda Pharmaceutical Company (Japan) Recent Developments
- 12.2 Nestle (Switzerland)
- 12.2.1 Nestle (Switzerland) Company Information
- 12.2.2 Nestle (Switzerland) Business Overview
- 12.2.3 Nestle (Switzerland) Revenue in IBS Treatment Business (2021-2026)
- 12.2.4 Nestle (Switzerland) IBS Treatment Product Portfolio
- 12.2.5 Nestle (Switzerland) Recent Developments
- 12.3 Novartis (Switzerland)
- 12.3.1 Novartis (Switzerland) Company Information
- 12.3.2 Novartis (Switzerland) Business Overview
- 12.3.3 Novartis (Switzerland) Revenue in IBS Treatment Business (2021-2026)
- 12.3.4 Novartis (Switzerland) IBS Treatment Product Portfolio
- 12.3.5 Novartis (Switzerland) Recent Developments
- 12.4 Pfizer (U.S.)
- 12.4.1 Pfizer (U.S.) Company Information
- 12.4.2 Pfizer (U.S.) Business Overview
- 12.4.3 Pfizer (U.S.) Revenue in IBS Treatment Business (2021-2026)
- 12.4.4 Pfizer (U.S.) IBS Treatment Product Portfolio
- 12.4.5 Pfizer (U.S.) Recent Developments
- 12.5 Synthetic Biologics (U.S.)
- 12.5.1 Synthetic Biologics (U.S.) Company Information
- 12.5.2 Synthetic Biologics (U.S.) Business Overview
- 12.5.3 Synthetic Biologics (U.S.) Revenue in IBS Treatment Business (2021-2026)
- 12.5.4 Synthetic Biologics (U.S.) IBS Treatment Product Portfolio
- 12.5.5 Synthetic Biologics (U.S.) Recent Developments
- 12.6 Synergy Pharmaceuticals (U.S.)
- 12.6.1 Synergy Pharmaceuticals (U.S.) Company Information
- 12.6.2 Synergy Pharmaceuticals (U.S.) Business Overview
- 12.6.3 Synergy Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2021-2026)
- 12.6.4 Synergy Pharmaceuticals (U.S.) IBS Treatment Product Portfolio
- 12.6.5 Synergy Pharmaceuticals (U.S.) Recent Developments
- 12.7 Sucampo Pharmaceuticals (U.S.)
- 12.7.1 Sucampo Pharmaceuticals (U.S.) Company Information
- 12.7.2 Sucampo Pharmaceuticals (U.S.) Business Overview
- 12.7.3 Sucampo Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2021-2026)
- 12.7.4 Sucampo Pharmaceuticals (U.S.) IBS Treatment Product Portfolio
- 12.7.5 Sucampo Pharmaceuticals (U.S.) Recent Developments
- 12.8 Sebela Pharmaceuticals (Ireland)
- 12.8.1 Sebela Pharmaceuticals (Ireland) Company Information
- 12.8.2 Sebela Pharmaceuticals (Ireland) Business Overview
- 12.8.3 Sebela Pharmaceuticals (Ireland) Revenue in IBS Treatment Business (2021-2026)
- 12.8.4 Sebela Pharmaceuticals (Ireland) IBS Treatment Product Portfolio
- 12.8.5 Sebela Pharmaceuticals (Ireland) Recent Developments
- 12.9 RedHill Biopharma (Israel)
- 12.9.1 RedHill Biopharma (Israel) Company Information
- 12.9.2 RedHill Biopharma (Israel) Business Overview
- 12.9.3 RedHill Biopharma (Israel) Revenue in IBS Treatment Business (2021-2026)
- 12.9.4 RedHill Biopharma (Israel) IBS Treatment Product Portfolio
- 12.9.5 RedHill Biopharma (Israel) Recent Developments
- 12.10 Protagonist Therapeutics (U.S.)
- 12.10.1 Protagonist Therapeutics (U.S.) Company Information
- 12.10.2 Protagonist Therapeutics (U.S.) Business Overview
- 12.10.3 Protagonist Therapeutics (U.S.) Revenue in IBS Treatment Business (2021-2026)
- 12.10.4 Protagonist Therapeutics (U.S.) IBS Treatment Product Portfolio
- 12.10.5 Protagonist Therapeutics (U.S.) Recent Developments
- 12.11 Probi (Sweden)
- 12.11.1 Probi (Sweden) Company Information
- 12.11.2 Probi (Sweden) Business Overview
- 12.11.3 Probi (Sweden) Revenue in IBS Treatment Business (2021-2026)
- 12.11.4 Probi (Sweden) IBS Treatment Product Portfolio
- 12.11.5 Probi (Sweden) Recent Developments
- 12.12 Lexicon Pharmaceuticals (U.S.)
- 12.12.1 Lexicon Pharmaceuticals (U.S.) Company Information
- 12.12.2 Lexicon Pharmaceuticals (U.S.) Business Overview
- 12.12.3 Lexicon Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2021-2026)
- 12.12.4 Lexicon Pharmaceuticals (U.S.) IBS Treatment Product Portfolio
- 12.12.5 Lexicon Pharmaceuticals (U.S.) Recent Developments
- 12.13 Ironwood Pharmaceuticals (U.S.)
- 12.13.1 Ironwood Pharmaceuticals (U.S.) Company Information
- 12.13.2 Ironwood Pharmaceuticals (U.S.) Business Overview
- 12.13.3 Ironwood Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2021-2026)
- 12.13.4 Ironwood Pharmaceuticals (U.S.) IBS Treatment Product Portfolio
- 12.13.5 Ironwood Pharmaceuticals (U.S.) Recent Developments
- 12.14 Ipsen (France)
- 12.14.1 Ipsen (France) Company Information
- 12.14.2 Ipsen (France) Business Overview
- 12.14.3 Ipsen (France) Revenue in IBS Treatment Business (2021-2026)
- 12.14.4 Ipsen (France) IBS Treatment Product Portfolio
- 12.14.5 Ipsen (France) Recent Developments
- 12.15 Innovate Biopharmaceuticals (U.S.)
- 12.15.1 Innovate Biopharmaceuticals (U.S.) Company Information
- 12.15.2 Innovate Biopharmaceuticals (U.S.) Business Overview
- 12.15.3 Innovate Biopharmaceuticals (U.S.) Revenue in IBS Treatment Business (2021-2026)
- 12.15.4 Innovate Biopharmaceuticals (U.S.) IBS Treatment Product Portfolio
- 12.15.5 Innovate Biopharmaceuticals (U.S.) Recent Developments
- 12.16 Bausch Health
- 12.16.1 Bausch Health Company Information
- 12.16.2 Bausch Health Business Overview
- 12.16.3 Bausch Health Revenue in IBS Treatment Business (2021-2026)
- 12.16.4 Bausch Health IBS Treatment Product Portfolio
- 12.16.5 Bausch Health Recent Developments
- 12.17 AstraZeneca (U.K)
- 12.17.1 AstraZeneca (U.K) Company Information
- 12.17.2 AstraZeneca (U.K) Business Overview
- 12.17.3 AstraZeneca (U.K) Revenue in IBS Treatment Business (2021-2026)
- 12.17.4 AstraZeneca (U.K) IBS Treatment Product Portfolio
- 12.17.5 AstraZeneca (U.K) Recent Developments
- 12.18 Astellas Pharma (Japan)
- 12.18.1 Astellas Pharma (Japan) Company Information
- 12.18.2 Astellas Pharma (Japan) Business Overview
- 12.18.3 Astellas Pharma (Japan) Revenue in IBS Treatment Business (2021-2026)
- 12.18.4 Astellas Pharma (Japan) IBS Treatment Product Portfolio
- 12.18.5 Astellas Pharma (Japan) Recent Developments
- 12.19 Ardelyx (U.S.)
- 12.19.1 Ardelyx (U.S.) Company Information
- 12.19.2 Ardelyx (U.S.) Business Overview
- 12.19.3 Ardelyx (U.S.) Revenue in IBS Treatment Business (2021-2026)
- 12.19.4 Ardelyx (U.S.) IBS Treatment Product Portfolio
- 12.19.5 Ardelyx (U.S.) Recent Developments
- 12.20 Allergan (Ireland)
- 12.20.1 Allergan (Ireland) Company Information
- 12.20.2 Allergan (Ireland) Business Overview
- 12.20.3 Allergan (Ireland) Revenue in IBS Treatment Business (2021-2026)
- 12.20.4 Allergan (Ireland) IBS Treatment Product Portfolio
- 12.20.5 Allergan (Ireland) Recent Developments
- 12.21 Alfasigma USA (Italy)
- 12.21.1 Alfasigma USA (Italy) Company Information
- 12.21.2 Alfasigma USA (Italy) Business Overview
- 12.21.3 Alfasigma USA (Italy) Revenue in IBS Treatment Business (2021-2026)
- 12.21.4 Alfasigma USA (Italy) IBS Treatment Product Portfolio
- 12.21.5 Alfasigma USA (Italy) Recent Developments
- 12.22 Abbott Laboratories (U.S.)
- 12.22.1 Abbott Laboratories (U.S.) Company Information
- 12.22.2 Abbott Laboratories (U.S.) Business Overview
- 12.22.3 Abbott Laboratories (U.S.) Revenue in IBS Treatment Business (2021-2026)
- 12.22.4 Abbott Laboratories (U.S.) IBS Treatment Product Portfolio
- 12.22.5 Abbott Laboratories (U.S.) Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst